Emgality ® (galkanezumab)

För fullständig produktresumé för Emgality® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Emgality® ▼ (galcanezumab): Information om borttagning av locket

Låt skyddet vara på tills du är klar att injicera.

Uncap the Pen

Make sure the pen is locked. Leave the base cap on until you are ready to inject.

  • When you are ready to inject, twist off the base cap and throw it away in the bin.

  • Do not put the base cap back on – this could damage the needle.

  • Do not touch the needle.1

What if I accidentally removed the base cap

The medicine must be injected immediately after the base cap is removed. Do not remove the base cap until you are ready to inject your dose. Here is why:

  • If the base cap is removed and the injection is not given immediately, the medicine can dry in the needle pathway. This can cause the needle to clog. If the needle is clogged, the pen will not deliver the dose.

  • The base cap keeps the needle sterile and protects the patient from an accidental needlestick. Do not store the pen without the base cap on it because dirt or bacteria can get into the needle.2

If the base cap was removed and it is not time for your injection, dispose of the pen and get a new one.2 

What if I unlocked the pen and pressed the teal injection button before I twisted off the base cap

Do not remove the base cap. Dispose of the pen and get a new one.1

The instructions for using the pen included with the Package Leaflet, must be followed carefully. The pre-filled pen is for total use only.3

After training, patients may self-inject galcanezumab if a healthcare professional determines that it is appropriate. 3

References

1. Emgality [instructions for use]. Eli Lilly Nederland B.V., The Netherlands.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

3. Emgality [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Datum fӧr senaste ӧversyn 2019 M02 15


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss